Original Paper

A Comparison of Stent Implant versus Medical Treatment for Severe Symptomatic Intracranial Stenosis: A Controlled Clinical Trial

Reza Mohammadian^a Ali Pashapour^a Ehsan Sharifipour^a
Reza Mansourizadeh^b Farideh Mohammadian^a
Ali Akbar Taher Aghdam^a Mohammad Mousavi^a
Farhad Dadras^c

^aNeuroscience Research Center, Tabriz University of Medical Sciences,

^bNeurology Department, Alinasab Hospital, and ^cNeurology Department, Mahalati Hospital, Tabriz, Iran

Key Words

Ischemic stroke • Intracranial stenosis • Balloon-mounted coronary bare metal stents • Self-expandable stents • Functional outcome • Primary adverse events • Secondary adverse events

Abstract

Background: Atherosclerotic stenosis of the major intracranial arteries is the most common cause of ischemic stroke. There are limited treatments for severe intracranial stenosis, and stent placement versus medical treatment remains controversial. The aim of this study was to compare functional outcomes of these two modalities in patients with severe symptomatic intracranial stenosis. **Methods:** At a single center, between 2008 and 2011, patients with angiographically demonstrated severe (70–90%) symptomatic intracranial atherosclerosis were divided into two groups: group A, which received only medical treatment, and group B, which underwent endovascular stent implant treatment. The severity and location of the stenosis was determined by digital subtraction angiography and the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) trial criteria in all patients. The exclusion criteria were: specific causes other than atherosclerosis, such as artery dissection, fibromuscular dysplasia, vasculitis, radiation and intracranial hemorrhage, focal neurological deficit that did not correlate to internal carotid artery or

middle cerebral artery stenosis. All procedures were done under light anesthesia. Technical success was defined as the reduction of stenosis to <30% with complete enveloping of the lesion after the procedure. Early and late adverse events and functional outcomes were compared between the groups using the modified Rankin Scale (mRS). **Results:** Overall, 63 patients (29 in group A and 34 in group B) were evaluated and followed for a mean period of 15.22 months (range 6–25). The technical success rate was 97% in a total of 34 stents in 34 patients. There was no difference between the early (within 30 days) adverse event rates of the two groups. The median follow-up duration for the stent implant patients was 15 months (range 6–25), and for the medically treated cohort it was 14 months (range 8–25). The re-stenosis rate was 5.8% and the total number of late (>30 days) adverse events, including stroke, myocardial infarction and death, was 1 (2.9%) and 6 (20.7%) in the stent implant and medical groups, respectively ($p = 0.042$). The stent implant group had significantly better favorable functional outcomes according to the mRS than the medical group (93.9 vs. 63.0%). The cumulative secondary adverse event-free survival was significantly lower in the stent implant group. **Conclusion:** Stent implants can be considered more durable and safe for patients with symptomatic severe stenosis of the internal carotid artery or middle cerebral artery, despite optimal medical therapy. Randomized, multicenter trials are required to confirm these results.

Copyright © 2012 S. Karger AG, Basel

Introduction

Stroke is the third leading cause of death and adult disability in North America, Europe, and Asia [1, 2]. Around the world, the most common cause of ischemic stroke is probably atherosclerotic stenosis of the major intracranial arteries [3, 4]. Patients with a similar degree of arterial stenosis may have a different prognosis depending on the ensuing cerebral flow status [5]. There are limited options for treatment of intracranial stenosis. Medical therapy with antiplatelet and antithrombotic agents has been widely used, but there is a high rate of failure, and such problems have spurred interest in endovascular treatment approaches [6]. However, a recent historical cohort study on severe intracranial stenosis of 70–99% demonstrated that aggressive medical management was superior to endovascular stent implantation [7, 8]. Considering these uncertainties regarding the safety and efficacy of medical therapy alone, as compared with intracranial stent implantation, we designed this study to compare the outcomes of these two therapeutic approaches in patients with severe (70–90%) symptomatic intracranial stenosis in the territory of the middle cerebral artery (MCA) or internal carotid artery (ICA) presenting with transient ischemic attack (TIA) or ischemic stroke.

Materials and Methods

Subjects and Procedures

Sixty-three patients with symptomatic intracranial arterial stenosis, presenting with ischemic stroke or TIA, were referred to our institute and evaluated prospectively in a non-randomized study from September 2008 to December 2011. The diagnosis of ischemic stroke was based on a focal neurologic deficit with corresponding ischemic lesions demonstrated with spiral brain computed tomography (CT) and brain magnetic resonance imaging (MRI) after admission. Those that had severe (70–99%) stenosis of the intracranial ICA or MCA branches by magnetic resonance angiography (MRA) within the previous 21 days were included in our study (using convenient sampling). The severity and location of the stenosis

was determined by digital subtraction angiography and the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) trial criteria [9] in all patients.

The intensity of the neurological deficit at admission was assessed by neurologists using the National Institutes of Health Stroke Scale (NIHSS). We non-randomly categorized patients into two groups with an allocation sequence: the medical group, which received only medical treatment, and the stent implant group, which underwent endovascular balloon-mounted coronary bare metal stent (BMS) placement in a stenosis at the intracranial ICA and self-expandable stent (SES) placement in a MCA stenosis. The treatment decision was thoroughly evaluated by a team of neurologists and a neuroradiologist. The exclusion criteria were: specific causes other than atherosclerosis, such as artery dissection, fibromuscular dysplasia, vasculitis, radiation and intracranial hemorrhage, focal neurological deficit that did not correlate to ICA or MCA occlusion, a type C of Mori et al. [10] in MCA stenosis, and patients who underwent only endovascular angioplasty. For a matched comparison and to avoid selection bias, the vascular risk factors, anatomic location of the stenosis, stenosis degree, and baseline modified Rankin Scale (mRS) score and NIHSS score were all matched between the two groups (by frequency matching), as revealed in table 1.

A standard protocol was used for evaluation of all patients. Demographic features and vascular risk factors were recorded by an expert neurologist, including hypertension, diabetes mellitus, ischemic heart disease, dyslipidemia (defined as receiving lipid-lowering agents or having an overnight fasting cholesterol level >200 mg/dl and low-density lipoprotein >100 mg/dl), cigarette smoking, and previous TIA or stroke (table 1).

All paraclinical data of patients were evaluated as well, including red and white blood cell and platelet counts, blood glucose and glycosylate hemoglobin (HbA1c) levels, lipid profiles, serum electrolyte levels, liver transaminase levels, blood urea and creatinine levels, measurement of prothrombin and activated partial thromboplastin times, and evaluation with electrocardiography (data not shown). All patients received standard care ordered by the stroke care unit (antiplatelet, statin, and daily physiotherapy) and were usually discharged during 1 week after admission by a neurologist. After this time, the patients were recalled and a skilled neuroradiologist informed the patients about the benefits and potential risks of the endovascular stent implant therapy and offered them this treatment as an alternative. Patients who gave informed consent were transferred to the angiography room. These patients were required to have no contraindications for endovascular procedures (renal failure, coagulopathy, and contrast allergy). The rationale for the medical treatment of patients was that they refused the stent implant because of the procedural risk and/or the expense, although they were stent qualified. Also, a few patients desired a stent but had not been offered a stent implant due to technical difficulties.

Endovascular angioplasty and stent implantations were performed by the same interventional neuroradiologist that implemented angiography. All procedures were done under light anesthesia. All collateral flow to the infarcted cerebral hemisphere was systematically assessed. The artery that was clinically assumed to be involved was investigated last and, after this diagnostic angiography, endovascular therapy was performed directly.

A 7F guide catheter was placed into the proximal cervical ICA. The shortest coronary BMS that covered the full length of the stenotic segment was chosen, and the same technique for stenting of proximal ICA stenosis was deployed. However, for MCA stenosis, we used a SES. All patients received clopidogrel 75 mg/day and ASA 100 mg/day at least 3 days previous to the procedure and full heparinization during the procedure. ICA stenoses were distinguished with respect to the affected segment and included stenosis of the intracranial segment of the ICA from the initiation of the petrous segments up to the communicating segments, and MCA stenoses were classified as stenosis of this artery from the origin to the

Table 1. Patient characteristics according to treatment protocol

Characteristics	Stent-implanted group	Medically treated group	p value
Patients	34 (54.0)	29 (46.0)	
Gender			0.793
Male	20 (58.8)	18 (62.1)	
Female	14 (41.2)	11 (37.9)	
Age, years	67.88 ± 8.42	70.34 ± 6.99	0.484
Vascular risk factors			
Diabetes	24 (70.6)	17 (58.6)	0.321
Hypertension	24 (70.6)	20 (69.0)	0.889
Dyslipidemia	4 (11.7)	6 (20.6)	0.677
Cigarette smoking	12 (35.2)	15 (51.7)	0.198
Ischemic heart disease	11 (32.4)	14 (48.3)	0.247
Previous TIA or stroke	4 (11.7)	3 (10.3)	0.289
Presenting symptoms			0.987
Ischemic stroke	20 (58.8)	17 (58.6)	
TIA	14 (41.2)	12 (41.4)	
Lesion locations			0.233
ICA	18 (52.9)	11 (37.9)	
MCA	16 (47.1)	18 (62.1)	
Location of MCA occlusion			0.356
M1 segment	9 (26.5)	10 (34.5)	
M2 segment	7 (20.6)	8 (27.6)	
Location of ICA occlusion			
Cavernous	8 (23.5)	8 (27.6)	
Petrous	7 (20.6)	2 (6.9)	
Petrocavernous	3 (8.8)	1 (3.4)	
Length of stenosis (≥7 vs. <7 mm)	18 (52.9)	12 (41.3)	0.147
Functional status (initial mRS score)			0.867
2	4 (11.8)	2 (6.9)	
3	14 (42.2)	12 (41.4)	
4	6 (17.6)	7 (24.1)	
5	10 (29.4)	8 (27.6)	
Initial NIHSS	7.82 ± 3.05	7.59 ± 3.14	0.782
Stenosis degree at presentation, %	81.65 ± 1.26*	77.09 ± 1.45*	0.062
Stenosis degree distribution			0.055
70–80%	20 (58.8)	24 (82.8)	
81–90%	14 (41.2)	5 (17.2)	
Follow-up duration, months	15.18 ± 4.80	15.28 ± 4.76	0.802

Data are presented as means ± SD or numbers with percentages in parentheses. M1 = First segment of the MCA artery; M2 = second segment of the MCA artery.

* Data are presented as means ± standard error.

origin of the cortical branches of the horizontal (M1) and Sylvian (M2) segments, based on Ziyal et al. [11] and Mori et al. [10] nomenclature, respectively. To prevent hyperperfusion, patients were transferred to the intensive care unit for strict control of blood pressure and their general condition. To exclude any asymptomatic complications, brain MRI, including diffusion-weighted imaging and apparent diffusion coefficient mapping, was performed within 72 h following intervention.

Following the initial diagnosis, the medical group received double the antiplatelet regimen (aspirin 80 mg/daily, clopidogrel 75 mg/daily) for lifetime and atorvastatin (20 mg/daily) for at least 12 months. After the procedure, patients received the same treatment. All patients in each group underwent daily physiotherapy (if needed) by standard protocols in the same center. None of them switched to the other group.

Both groups were managed similarly and followed up clinically at 1 month and every 6 months after study enrolment until the end of the follow-up time, which was when the last included patient had been followed for 6 months. According to this definition, 5 patients in the medical group [3 had ICA severe stenosis (2 in cavernous and 1 in petrous segments) and 2 had MCA severe stenosis (1 in M1 and 1 in M2 segments), all of them by digital subtraction angiography], who did not agree with continuing follow-up, exited the study before the planned 6 months for follow-up MRI or transcranial Doppler (TCD), and their data were not evaluated. The follow-up exams were performed by independent neurologists (who were not involved in the interventional procedures) via outpatient visits and vascular risk factor management. During these visits, if new neurological signs occurred, which were suspected to be a stroke, the patient was examined by the study neurologist for future study by MRI or brain CT. Within the follow-up period, high blood pressure (systolic blood pressure was preferred to be <140 mm Hg, or <130 mm Hg if the patient was diabetic) and high blood sugar were treated aggressively and patients who smoked were asked to cease cigarette smoking along with participating in lifestyle modification programs including weight reduction, exercise, and maintaining a nutritional diet.

Technical success was defined as the reduction of stenosis to <30% with complete enveloping of the lesion after the procedure [12]. The stent implant group had scheduled follow-up brain MRI, MRA or TCD at 6 and 12 months after the procedure for examination of potential re-stenosis. In-stent re-stenosis was described as recurrent artery stenosis to the degree of >30% luminal narrowing after excluding post-stent implant residual stenosis. The re-stenosis degree and location were determined based on the suggested method of Samuels et al. [13] and increased flow velocity on follow-up TCD below or above the stent-implemented vessels. The occurrence of clinical adverse events (AEs) for all patients was evaluated 30 days after enrolment or after stent implantation, and then every 6 months until follow-up ended. The AEs were classified as occurring within 30 days and follow-up events. The within-30-days AEs were classified as happening during the 30 days after enrolment, including ischemic stroke in the territory or in another zone of the qualifying artery, symptomatic intracranial hemorrhage, and TIA. Follow-up AEs (FAEs) were defined as arising 30 days after enrolment during the follow-up period. The FAEs consisted of ischemic stroke (stroke in the territory of the qualifying artery), TIA, myocardial infarction, and mortality related to these events. In addition, the patients were informed of suggestive symptoms of AEs, and they were instructed to visit their physician as soon as possible if the 6-month visit had not occurred. The causes of death were obtained from relatives of the deceased patients. The mRS scores were calculated at the end of the follow-up period. Scores of 0–2 were classified as a favorable functional status and scores of 3–5 were categorized as an unfavorable functional status. Mortality was indicated by a score of 6.

Statistical Method

The study was designed to have >80% power to detect a 35% difference in the base of 5% change in the mRS score. Numerical variables are presented as mean $\pm$ SD and categorical variables were summarized by absolute frequencies and percentages. Continuous variables were compared using the Student's t test or a non-parametric Mann-Whitney U test whenever the data did not appear to have a normal distribution. Categorical variables were compared using a χ^2 or Fisher's exact test. The observation time was from the study enrolment

to within-30-days AEs, FAE occurrence, loss to follow-up, or the patient being event-free until 25 months. Univariate analyses for comparing within-30-days AEs and FAEs across the two groups of patients were then established and the associations are presented as odds ratios (ORs) with 95% confidence intervals (CIs). Time to events was analyzed by Kaplan-Meier and log-rank tests to compare the cumulative event rates and functional outcomes of the two groups. The proportional hazard assumption was checked to apply to the methods. For statistical analyses, the statistical software SPSS version 13.0 for Windows (SPSS Inc., Chicago, Ill., USA) was used. All p values were two-tailed, with statistical significance defined by $p \leq 0.05$.

Results

Overall, 63 patients were evaluated. For all patients, the mean age was 69.02 ± 7.72 years (range 44–82) and male gender was predominant (60.3%). Stents were implanted in 34 (54%) patients. There were no significant differences between the stent implant group and 29 matched patients in the medically managed group in terms of basic characteristics, follow-up time, baseline functional status, stenosis location, and degree of stenosis (all p values were >0.05 ; table 1). Overall, hypertension was found in 69.8% of the patients and was the most common vascular risk factor. A similar incidence was found for the presenting symptoms in the two groups including TIA and stroke (41.2 and 58.7%, respectively). ICA was involved in 46.0% of the patients, predominantly at the cavernous segment (25.3%), and MCA was involved in 53.9% of the patients, frequently at the M1 segment (30.1%). The mean degree of stenosis was approximately 79% at presentation in all patients, which was slightly higher in the stent implant group. Eighteen (52.9%) BMSs were implanted for ICA stenosis, while 16 (47.1%) SESs were implanted for MCA stenosis. There were no statistically significant differences in within-30-days AEs, FAEs, and re-stenosis rates between the two groups (data not shown). During the procedure, 6 patients had hypotension and bradycardia, which were treated with inotropes. Hypertension occurred in 2 patients who were treated with antihypertensive agents. All of these incidents were reversible, with complete recovery within 24 h of the procedure. The technical success rate was 97% in a total of 34 stents in 34 patients. The overall mean follow-up time was 15.22 ± 4.74 months. The median follow-up duration for the stent implant patients was 15 months (range 6–25) and for the medically treated cohort was 14 months (range 8–25). The in-stent re-stenosis rate in our study was 5.8%, which happened in 2 patients. In 1 patient, re-stenosis occurred 12 months after the procedure in the M1 segment stent and in the other patient at 15 months in the cavernous segment. Both patients were asymptomatic. The estimation of stenosis advancement was troublesome for the medically managed group because performing TCD and MRA were not desired during the follow-up period. The overall rate of within-30-days AEs in our study was 3.1% and there was no statistically significant difference in within-30-days AEs between the two groups ($p = 0.909$; table 2). The total incidence rate of FAEs in our survey was 11.1%, which was significantly higher (20.7%) in the medically managed patients during follow-up ($p = 0.042$; table 2). Most importantly, the stent implant group had significantly more favorable functional outcomes (mRS 2) than the medically managed group. Both groups began with a semi-equivalent distribution of baseline mRS (table 1) but terminated with a significant difference in functional outcomes and occurrences of FAEs, as illustrated by the Kaplan-Meier curves (fig. 1 and 2, respectively). The medically managed group had a progressively significant increase in unfavorable outcomes during the time after enrolment (93.9 vs. 63.0%, $p = 0.045$; fig. 1) and a significantly lower cumulative 15-month event-free survival rate (79.3 vs. 97.0%, $p = 0.0243$; fig. 2).

Table 2. Comparison of unfavorable functional status, AEs, and mortality rate between stent-implanted and medically managed group

Variables	Stent-implanted group (n = 34)	Medically treated group (n = 29)	p value
Favorable functional status	31 (93.9)	17 (63.0)	0.004
mRS 0	12 (35.3)	3 (10.3)	
mRS 1	11 (32.4)	8 (27.6)	
mRS 2	8 (23.5)	6 (20.7)	
Within-30-days AEs	1 (2.9)	1 (3.4)	0.909
Ischemic stroke*	1 (2.9)	0	
TIA	0	1 (3.4)	
FAEs	1 (2.9)	6 (20.7)	0.042
Ischemic stroke*	0	4 (13.8) ^b	0.040
Myocardial infarction	1 (2.9) ^a	2 (6.9) ^c	0.590
Mortality	1 (2.9)	2 (6.9)	0.590

Data are presented as numbers with percentages in parentheses.

* Stroke in the territory of the qualifying artery.

^a One 75-year-old male with MCA involvement presenting with ischemic stroke (mRS 2) died 11 months after the procedure because of fatal myocardial infarction.

^b Including a 71-year-old male with ICA involvement presenting with TIA (mRS 5) who died 10 months after the study with massive ischemic stroke in the territory of his qualified artery.

^c Including a 74-year-old male with MCA involvement presenting with ischemic stroke (mRS 5) who died 12 months after the study because of fatal myocardial infarction.

Discussion

Atherosclerotic stenosis of the major intracranial arteries is probably the most common cause of stroke [3]. Some ischemic stroke mechanisms that are secondary to intracranial atherosclerosis include intraplaque hemorrhage and the occlusive effect, thromboembolic events distal to the site of the stenosis, direct small penetrating artery occlusion at the site of the plaque and hypoperfusion [14]. Regarding the therapeutic modalities, there are ongoing discussions on the superiority of endovascular stent placement or medical management for intracranial stenosis treatment [15–18]. Despite antiplatelet medications, the annual risk of recurrent stroke is as high as 12% in patients with symptomatic intracranial atherosclerosis, and stenting and angioplasty have been performed in selected patients with severe stenosis refractory to medical treatment [19]. In this study, we compared within-30-days AEs and FAEs, unfavorable functional status (mRS >2), and event-free survival between the endovascular stent implant and medically managed groups that had angiographically documented severe intracranial stenosis (70–90%) in the ICA or MCA, with clinical follow-up.

This survey compared within-30-days AEs, FAEs, and unfavorable functional outcomes of 34 ICA or MCA stent-implanted cases with 29 matched medically treated patients. While there were no differences in the total within-30-days AE rate between the two groups (2.9 vs. 3.4%, $p = 0.909$), the FAE rate was lower in the stent implant group (2.9%) than in the medically managed group (20.7%, $p = 0.042$). The 1-year stroke rate in the medically managed group was 13.8%, which was significantly higher in comparison with the other group during follow-up ($p = 0.040$; table 2). The ischemic strokes in the medically treated group were mostly large cerebral infarctions within the territory of the stenotic artery during the 7–10 months after enrolment (fig. 2).

Time interval months		Patients entering this interval, n	Patients with-drawn during interval, n	Patients exposed to risk, n	Unfavorable functional outcome, n	Proportion of favorable functional outcome	Cumulative probability of favorable functional outcome at end of interval, %
0–4	Medical:	29	0	29	0	1.00	100
	Stent:	34	0	34	0	1.00	100
4–8	Medical:	29	0	29	0	1.00	100
	Stent:	34	3	32	0	1.00	100
8–12	Medical:	29	1	28	5	0.824	82.4
	Stent:	31	2	30	1	0.966	96.6
12–16	Medical:	23	6	20	4	0.800	65.9
	Stent:	28	12	22	1	0.954	92.2
16–20	Medical:	13	4	11	4	0.636	41.9
	Stent:	15	8	11	1	0.909	83.8
20–24	Medical:	5	3	3	0	1.00	41.9
	Stent:	6	4	4	0	1.00	83.8
24–28	Medical:	2	2	1	0	1.00	41.9
	Stent:	2	2	1	0	1.00	83.8

Fig. 1. Kaplan-Meier curve and table of cumulative probability of favorable functional outcome defined as mRS scores 0–2. Note that the medically managed group has a markedly worse functional outcome (mRS score 3–5) during follow-up ($p = 0.0047$).

The reported rates of periprocedure complications (within 30 days of the procedure) in endovascular stent implant patients have varied from 4.4 to 50% [20, 21]. In one study, medical care plus angioplasty with or without stent placement was compared with medical care alone. The overall 30-day rate of stroke and mortality was 7.9 and 3.4%, respectively [22]. In our cases, the periprocedure mortality and stroke rates were 0 and 2.9% (table 2), which was

Time interval months		Patients entering this interval, n	Patients with-drawn during interval, n	Patients exposed to risk, n	Secondary AEs, n	Proportion of event-free survival	Cumulative probability of event-free survival at end of interval, %
0–2	Medical:	29	0	29	0	1.00	100
	Stent:	34	0	34	0	1.00	100
2–4	Medical:	29	0	29	0	1.00	100
	Stent:	34	0	34	0	1.00	100
4–6	Medical:	29	0	29	0	1.00	100
	Stent:	34	0	34	0	1.00	100
6–8	Medical:	29	0	29	2	0.931	93.1
	Stent:	34	0	34	0	1.00	100
8–10	Medical:	27	0	27	2	0.925	86.2
	Stent:	34	0	34	1	0.970	97.0
10–12	Medical:	25	0	25	1	0.960	82.7
	Stent:	33	0	33	0	0.970	97.0
12–14	Medical:	24	0	24	1	0.958	79.3
	Stent:	33	33	16	0	0.970	97.0
14–16	Medical:	23	23	11	0	1.00	79.3
	Stent:	33	33	16	0	0.970	97.0

Fig. 2. Kaplan-Meier curve and table of cumulative secondary AE-free survival including mortality. Note that all AEs occurred within 6–12 months after enrolment of patients.

more acceptable than other reported results. The periprocedure ischemic stroke in our study occurred in a 63-year-old female with a history of diabetes mellitus, hypertension, hyperlipidemia, and cigarette smoking. She had an ischemic stroke (mRS 3) during the first week after her procedure. The reported success rates of implantation of intracranial stents have been >95% [23, 24]. Henkes et al. [25] investigated stent implantation and reported that the technical success rate was 97%. The technical success rate for stent implantation was 97% in

our study, which was in accordance with previously reported success rates [an unsuccessful stent implantation occurred in our patient who had residual stenosis (60%) in the MCA]. The ischemic stroke and mortality rates after the procedure have ranged from 3.2 to 10% [26–28]. Suh et al. [29] reported on cases with intracranial stenosis that were $\geq 70\%$ and were treated with various types of BMS. Their reported re-stenosis rate was 0% and the ischemic stroke and mortality rate was 10% within 6 months of follow-up [29]. In the SSYLIVIA trial, after applying BMSs, strokes occurred in 6.6% of the treated patients within 30 days and in 7.3% between 30 days and 1 year. Re-stenosis occurred in 35% of the patients within 6 months after the procedure [30]. Gröschel et al. [20] performed a systematic review of outcomes after stenting for intracranial atherosclerosis and the re-stenosis rates were 34.6 and 16.1% for SES and BMS, respectively. Interestingly, our AE rates were lower than reported in these studies and there was no statistical significance in the re-stenosis rates between SESs (6.2%) and BMSs (5.5%). However, the BMS had a significant limitation because there was a technically difficult delivery to the convoluted intracranial vessels. The lower rates of re-stenosis and AEs in these cases could reflect the proper modification of risk factors and the attentiveness of our team. In the present investigation, all AEs in stent implant patients occurred within 6–12 months after the procedure, suggesting little profit in delayed stent implantation after 1 year.

Jarvis et al. [31] demonstrated that stent implant patients with 70–99% stenosis had better stroke or mortality rates during the initial 30 days. They also had a better ipsilateral stroke rate beyond 30 days in comparison with the medically managed group [31], which was in accordance with our results. Dramatically, the stent implant group had a significantly lower unfavorable functional outcome rate than medically treated cases (fig. 1). This might arise from superior compliance in vascular risk factor control, ameliorated cerebrovascular auto-regulation, scant in-stent re-stenosis, and a lower incidence of AEs. In contrast to the above-mentioned results, Samaniego et al. [32] revealed a similar combined ischemic event rate and unfavorable functional outcome rate in medically managed and stent implant patients with intracranial stenosis. It was demonstrated that patients with poor control of risk factors, such as elevated low-density lipoprotein and blood pressure, had higher rates of recurrent vascular events [33–35].

A lower rate of ischemic stroke in stent implant cases versus medically managed cases (2.9 vs. 20.7%) was obtained with the same optimal management of blood pressure and lipid profiles in both groups. Patients in the WASID trial who were treated with aspirin or warfarin and standard management of risk factors had a 10.7% 30-day rate of stroke or death and a 25% 1-year rate for primary events [9]. In our medically managed patients, the 30-day rate of stroke or death and 1-year stroke rate were 0 and 13.8%, respectively, which is lower than prior results. One possible explanation is that the combination of aspirin and clopidogrel played an important role in reducing the early risk of stroke. This conclusion is in accordance with the results of Wong et al. [36]. Because patients with 70–99% stenosis are at the highest risk for complications with medical therapy rather than stent implantation, the benefit of stenting is likely to be greater in the severe stenosis group [37, 38]. Kasner et al. [37] demonstrated that patients with stenosis of $\geq 70\%$ of a major intracranial artery, despite medical therapy and standard vascular risk factor modification, had a recurrent stroke rate of 23% at 1 year, particularly in the territory of the stenotic artery, which is in agreement with the above results.

Study Limitations

The comparison of stent implant and medically managed groups was done using univariate analysis. There are some limitations in our study. The number of patients was small (due to a limitation of eligible patients during the study period). Also, we excluded some pa-

tients and therefore missed a number of patients who were eligible for stent placement or medical treatment. For this reason, we could not evaluate the predictive factors of morbidities.

Conclusion

The total event rate with severe intracranial stenosis in the stent implant group was lower than in the medically managed group during a mean period of 15.22 months of follow-up. The final functional outcome was better in the stent implant group, partially due to the lower occurrence of AEs. This study was not designed to confine the potential impact of risk factor management on long-term outcomes. Therefore, we suggest that endovascular angioplasty with stent implantation could be considered for patients with symptomatic severe intracranial stenosis of the ICA or MCA as a safer and more durable approach, despite optimal medical therapy. A randomized, multicenter, parallel trial may be required to compare the clinical efficacy of these two treatment modalities for symptomatic intracranial stenosis.

References

- 1 Donnan GA, Fisher M, Macleod M, Davis SM: Stroke. *Lancet* 2008;371:1612–1623.
- 2 Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al: Heart disease and stroke statistics – 2006 update. *Circulation* 2006;113:e85–e151.
- 3 Gorelick PB, Wong KS, Bae HJ, Pandey DK: Large artery intracranial occlusive disease: a large worldwide burden but a relatively neglected frontier. *Stroke* 2008;39:2396–2399.
- 4 Wong LK: Global burden of intracranial atherosclerosis. *Int J Stroke* 2006;1:158–159.
- 5 Lau AY, Wong EH, Wong A, Mok VC, Leung TW, Wong KS: Significance of good collateral compensation in symptomatic intracranial atherosclerosis. *Cerebrovasc Dis* 2012;33:517–524.
- 6 Turan TN, Derdeyn CP, Fiorella D, Chimowitz MI: Treatment of atherosclerotic intracranial arterial stenosis. *Stroke* 2009;40:2257–2261.
- 7 Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, et al: Stenting versus aggressive medical therapy for intracranial arterial stenosis. *N Engl J Med* 2011;365:993–1003.
- 8 Abou-Chebl A, Steinmetz H: Critique of ‘Stenting versus aggressive medical therapy for intracranial arterial stenosis’. *Stroke* 2012;43:616–620.
- 9 Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, et al: Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. *N Engl J Med* 2005;352:1305–1316.
- 10 Mori T, Fukuoka M, Kazita K, Mori K: Follow-up study after intracranial percutaneous transluminal cerebral balloon angioplasty. *Am J Neuroradiol* 1998;19:1525–1533.
- 11 Ziyal IM, Ozgen T, Sekhar LN, Ozcan OE, Cekirge S: Proposed classification of segments of the internal carotid artery: anatomical study with angiographical interpretation. *Neurol Med Chir (Tokyo)* 2005;45:184–191.
- 12 Qureshi AI, Kirmani JF, Harris-Lane P, Divani AA, Ahmed S, Ebrihimi A, et al: Vertebral artery origin stent placement with distal protection: technical and clinical results. *Am J Neuroradiol* 2006;27:1140–1145.
- 13 Samuels OB, Joseph GJ, Lynn MJ, Smith HA, Chimowitz MI: A standardized method for measuring intracranial arterial stenosis. *AJNR Am J Neuroradiol* 2000;21:643–646.
- 14 Higashida RT, Meyers PM, Connors JJ, Sacks D, Strother CM, Barr JD, et al: Intracranial angioplasty and stenting for cerebral atherosclerosis: a position statement of the American Society of Interventional and Therapeutic Neuroradiology, Society of Interventional Radiology, and the American Society of Neuroradiology. *Am J Neuroradiol* 2005;26:2323–2327.

- 15 Qureshi AI, Feldmann E, Gomez CR, Johnston SC, Kasner SE, Quick DC, et al: Consensus conference on intracranial atherosclerotic disease: rationale, methodology, and results. *J Neuroimaging* 2009;19:1S–10S.
- 16 Higashida RT, Meyers PM, Connors JJ, Sacks D, Strother CM, Barr JD, et al: Intracranial angioplasty and stenting for cerebral atherosclerosis: a position statement of the American Society of Interventional and Therapeutic Neuroradiology, Society of Interventional Radiology, and the American Society of Neuroradiology. *J Vasc Interv Radiol* 2005;16:1281–1285.
- 17 Marks MP: Is there a future for endovascular treatment of intracranial atherosclerotic disease after stenting and aggressive medical management for preventing recurrent stroke and intracranial stenosis (SAMMPRIS)? *Stroke* 2012;43:580–584.
- 18 Qureshi AI, Feldmann E, Gomez CR, Johnston SC, Kasner SE, Quick DC, et al: Intracranial atherosclerotic disease: an update. *Ann Neurol* 2009;66:730–738.
- 19 Choi JW, Kim JK, Choi BS, Lim HK, Kim SJ, Kim JS, et al: Angiographic pattern of symptomatic severe M1 stenosis: comparison with presenting symptoms, infarct patterns, perfusion status, and outcome after recanalization. *Cerebrovasc Dis* 2010;29:297–303.
- 20 Gröschel K, Schnaudigel S, Pilgram SM, Wasser K, Kastrup A: A systematic review on outcome after stenting for intracranial atherosclerosis. *Stroke* 2009;40:e340–e347.
- 21 Fiorella D, Chow MM, Anderson M, Woo H, Rasmussen PA, Masaryk TJ: A 7-year experience with balloon-mounted coronary stents for the treatment of symptomatic vertebrobasilar intracranial atheromatous disease. *Neurosurgery* 2007;61:236–242.
- 22 Cruz-Flores S, Diamond AL: Angioplasty for intracranial artery stenosis. *Cochrane Database Syst Rev* 2006;3:CD004133.
- 23 Jiang WJ, Srivastava T, Gao F, Du B, Dong KH, Xu XT: Perforator stroke after elective stenting of symptomatic intracranial stenosis. *Neurology* 2006;66:1868–1872.
- 24 Mazighi M, Yadav JS, Abou-Chebl A: Durability of endovascular therapy for symptomatic intracranial atherosclerosis. *Stroke* 2008;39:1766–1769.
- 25 Henkes H, Miloslavski E, Lowens S, Reinartz J, Liebig T, Kuhne D: Treatment of intracranial atherosclerotic stenoses with balloon dilatation and self-expanding stent deployment (Wingspan). *Neuroradiology* 2005;47:222–228.
- 26 Marks MP, Wojak JC, Al-Ali F, Jayaraman M, Marcellus ML, Connors JJ, et al: Angioplasty for symptomatic intracranial stenosis: clinical outcome. *Stroke* 2006;37:1016–1020.
- 27 Bose A, Hartmann M, Henkes H, Liu HM, Teng MM, Szikora I, et al: A novel, self-expanding, nitinol stent in medically refractory intracranial atherosclerotic stenosis: the Wingspan study. *Stroke* 2007;38:1531–1537.
- 28 Wolfe BF, Hussain SI, Lynch JR, Zaidat OO: Long term clinical and angiographic outcomes with the Wingspan stent for treatment of symptomatic 50–99% intracranial atherosclerosis: single center experience in 51 cases. *J Neurointerv Surg* 2009;1:40–43.
- 29 Suh DC, Kim JK, Choi JW, Choi BS, Pyun HW, Choi YJ, et al: Intracranial stenting of severe symptomatic intracranial stenosis: results of 100 consecutive patients. *Am J Neuroradiol* 2008;29:781–785.
- 30 SSVLIVA Study Investigators: Stenting of symptomatic atherosclerotic lesions in the vertebral or intracranial arteries (SSVLIVA): study results. *Stroke* 2004;35:1388–1392.
- 31 Jarvis AL, Chimowitz M, Lynn MJ, Alexander MJ, et al; NIH Multicenter Wingspan Intracranial Stent Study Group: Outcome of patients with 50–99% intracranial stenosis and TIA or stroke on antithrombotic therapy treated medically vs. stenting. Presented at: 60th Annual Meeting of the American Academy of Neurology, Chicago, IL, 2008.
- 32 Samaniego EA, Hetzel S, Thirunarayanan S, Aagaard-Kienitz B, Turk AS, Levine R: Outcome of symptomatic intracranial atherosclerotic disease. *Stroke* 2009;40:2983–2987.
- 33 PROGRESS Collaborative Group: Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack. *Lancet* 2001;358:1033–1041.
- 34 Chaturvedi S, Turan TN, Lynn MJ, Kasner SE, Romano J, Cotsonis G, et al; WASID Study Group: Risk factor status and vascular events in patients with symptomatic intracranial stenosis. *Neurology* 2007;69:2063–2068.
- 35 Turan TN, Cotsonis G, Lynn MJ, Chaturvedi S, Chimowitz M; Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators: Relationship between blood pressure and stroke recurrence in patients with intracranial arterial stenosis. *Circulation* 2007;115:2969–2975.

Mohammadian et al.: A Comparison of Stent Implant versus Medical Treatment for Severe Symptomatic Intracranial Stenosis: A Controlled Clinical Trial

- 36 Wong KS, Chen C, Fu J, Chang HM, Suwanwela NC, Huang YN, et al: Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomized, open-label, blinded-endpoint trial. *Lancet Neurol* 2010;9:489–497.
- 37 Kasner S, Chimowitz M, Lynn M, Howlett-Smith H, Stern BJ, Hertzberg VS, et al: Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. *Circulation* 2006;113:555–563.
- 38 Jiang WJ, Xu XT, Du B, Dong KH, Jin M, Wang QH, et al: Comparison of elective stenting of severe vs. moderate intracranial atherosclerotic stenosis. *Neurology* 2007;68:420–426.